- Trial phase
- Approved (Pfizer)
- Time to market
- Paxlovid is already approved and marketed by Pfizer. Enanta has no timeline to market for any of its own pipeline drugs; zelicapavir's registrational Phase 2b/3 data is expected in 2027, with potential FDA submission following positive results.
- Why 3/10
- Paxlovid is an already-approved, marketed drug owned by Pfizer (PFE), not Enanta. Enanta's connection was through patent litigation that has now fully concluded against Enanta (US Federal Circuit invalidated the '953 patent June 2026, en banc denied September 2026; UPC invalidated European patent October 29, 2026). There is no upcoming binary catalyst for Enanta related to Paxlovid. Enanta's next hard catalyst is Q4 2026 earnings on November 16, 2026, which is an earnings report, not a drug catalyst. ImpactScore is 3 because Paxlovid is an approved drug with no pending regulatory decision for Enanta, and the litigation that connected Enanta to Paxlovid has fully resolved.
Paxlovid is Pfizer's drug, not Enanta's. Enanta's patent litigation against Pfizer over Paxlovid has now been fully resolved against Enanta on both sides of the Atlantic: the US Federal Circuit invalidated the '953 patent in June 2026 (en banc denied September 2026), and the UPC invalidated the European EP 265 patent on October 29, 2026. With no further appeal options disclosed, the litigation catalyst is dead. Enanta's stock now trades entirely on its RSV pipeline (zelicapavir Phase 2b/3 RESOLVE trial, topline 2027; EDP-323 Phase 2a) and its AbbVie royalty revenue stream. The next hard catalyst is Q4 2026 earnings on November 16, 2026.
Price Chart
Executive Summary
Paxlovid is Pfizer's (PFE) FDA-approved oral antiviral for COVID-19, not a drug owned or developed by Enanta Pharmaceuticals (ENTA). Enanta's connection to Paxlovid was purely through patent litigation: it sued Pfizer alleging Paxlovid infringed its patents. That litigation has now fully failed. The US Federal Circuit invalidated Enanta's '953 patent in June 2026 and denied en banc rehearing in September 2026. The European Unified Patent Court invalidated Enanta's EP 265 patent on October 29, 2026 (yesterday), ending the EU case. Enanta is a clinical-stage biotech with no approved products; its revenue comes from AbbVie HCV drug royalties. Its pipeline focuses on RSV antivirals (zelicapavir in a registrational Phase 2b/3 trial that began dosing October 26, 2026; EDP-323 in Phase 2a). With the Paxlovid patent litigation fully resolved against Enanta, the stock's thesis now rests entirely on its RSV pipeline and AbbVie royalty stream.
How It Works
Paxlovid is a combination of two antiviral pills: nirmatrelvir (which blocks a key enzyme the SARS-CoV-2 virus needs to replicate) and ritonavir (which boosts nirmatrelvir levels in the body by slowing its breakdown). It is taken orally for five days to treat mild-to-moderate COVID-19 in high-risk adults.
Trial Status
Paxlovid is fully approved by the FDA (NDA 217188) for treatment of mild-to-moderate COVID-19 in high-risk adults. It was initially authorized under EUA in December 2021 and received full FDA approval in May 2023. Enanta's own pipeline: zelicapavir (RSV N-protein inhibitor) is in a registrational Phase 2b/3 trial (RESOLVE) that began dosing October 26, 2026, with topline Phase 2b data expected in 2027; EDP-323 (RSV L-protein inhibitor) completed a positive Phase 2a human challenge study in 2024-2025; EDP-978 is in Phase 1.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings report on November 16, 2026 (after market close)
- Zelicapavir Phase 2b topline data from RESOLVE trial expected in 2027
- Zelicapavir pediatric Phase 2b data expected in 2027
- CEO succession announcement (Jay Luly retiring by February 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ENANTA PHARMACEUTICALS INC 8-K ENTA ·Originating report